Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. filed a Form 8-K on January 5, 2023, under Item 2.02 to report the issuance of preliminary results for the year ended December 31, 2022. The filing covers the company’s common stock, traded under the symbol XERS on The Nasdaq Global Select Market.
Financial Metrics
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. It states that preliminary 2022 results were announced in a press release furnished as Exhibit 99.1, but that exhibit’s contents are not included in the provided text.
Material Changes Versus Prior Period
The filing text does not provide sufficient information to assess changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are described in the provided filing text beyond the announcement of preliminary year-end 2022 results.
Investor Verification Checklist
- Review Exhibit 99.1 for the preliminary 2022 financial results and any year-over-year comparisons.
- Verify whether the preliminary figures were subsequently revised in the company’s audited annual report or later filings.
- Confirm revenue, operating expenses, net loss, cash and equivalents, debt, cash usage, and liquidity information in the subsequent annual filing.
- Review any guidance, business updates, or risk disclosures included in the referenced press release.